CLDX: Deep Dive Ahead of Barzolvolimab's Phase 2 Prurigo Nodularis Readout—Raising Price Target to $54

Research evidence excerpt

CLDX: Deep Dive Ahead of Barzolvolimab's Phase 2 Prurigo Nodularis Readout—Raising Price Target to $54

Celldex Therapeutics, Inc. Equity Research

Central drivers: Type 2 and Non–Type 2 inflammation & neuro-immune dysregulation. At a

biological level, PN is marked by Type 2 (Th2) immune activation, with key cytokines including IL-4,

IL-13, and IL-31— the latter playing a central role as a direct mediator in itch signaling. This immune

activation is also accompanied by cutaneous neural dysregulation, including increased intraepidermal

nerve fiber density and upregulation of pruritogenic mediators such as substance P (SP) and nerve

growth factor (NGF), leading to heightened itch sensitivity. Importantly, neural sensitization appears

to sustain disease activity, even in the absence of external triggers. Concurrent skin barrier dysfunction

further exacerbates immune activation and sensory nerve stimulation, reinforcing disease chronicity.

Overall, the abnormal crosstalk between the peripheral nervous system and the immune system in the

skin, results in heightened itch signaling and chronic inflammation:

• Lesional skin exhibits structural and functional alterations in sensory nerve fibers, including nerve

hypertrophy, altered intraepidermal nerve density, and increased expression of neuropeptides

such as substance P and calcitonin gene-related peptide (CGRP), which amplify pruritus and

inflammation and promote long-term neuronal hypersensitivity.

• This neural dysfunction is tightly linked with immune activation, particularly involving mast cells,

eosinophils, macrophages, and T cells, which release pruritogenic cytokines and growth factors

that further sensitize nerves. The result is a positive feedback loop: 1) itch provokes scratching, 2)